Acinetobacter Baumannii News and Research

RSS

Temple University, URMC partner to translate novel medical research into new drugs

The University of Rochester Medical Center (URMC) and Temple University School of Pharmacy have announced a partnership that will help translate novel medical research into new drugs for treating diseases.

19 Aug 2011

Cubist initiates CXA-201 Phase 3 trial in complicated urinary tract infections

Cubist Pharmaceuticals, Inc. today announced the initiation of a pivotal Phase 3 trial of CXA-201 in patients with complicated urinary tract infections.

1 Aug 2011

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly-resistant bacteria, commonly referred to as 'superbugs.'

16 Apr 2011

IDSA develops plans to combat deadly antibiotic-resistant 'super bugs'

To head off a health care disaster, the Infectious Diseases Society of America has developed a plan to combat deadly antibiotic-resistant "super bugs" and is rolling out the multi-pronged plan today, on World Health Day 2011.

8 Apr 2011

Tru-D UV-C device effective in reducing pathogens on all environmental surfaces in hospital patient rooms

Results of an eight-month hospital study, "Room Decontamination with UV Radiation," were published in the October 2010 issue of "Infection Control and Hospital Epidemiology." The study evaluated the ability of an automated UV device, Tru-D, to decontaminate patient rooms contaminated with MRSA, VRE, C. difficile and a MDR strain of Acinetobacter baumannii.

10 Dec 2010

Stratatech receives SBIR grant to develop anti-infective living human skin substitute

Stratatech Corp., a privately-held regenerative medicine company, today announced that it has been awarded a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute.

17 Nov 2010

NIAID announces four new contracts for clinical trials to address problem of antimicrobial resistance

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced four new contracts for large-scale clinical trials that address the problem of antimicrobial resistance.

20 Oct 2010

NC State receives $1.8M defense grant to test molecule efficacy against antibiotic-resistant infections

A new $1.8 million grant from the Department of Defense will allow North Carolina State University researchers to work with the Walter Reed Institute of Research to further test the effectiveness of molecules that have shown great promise in combating antibiotic-resistant infections.

23 Sep 2010

New antibacterial peptide effective against infections in burn or blast wounds

An antibacterial peptide developed by Laszlo Otvos, a research professor of biology in Temple's College of Science and Technology, looks to be a highly-effective therapy against infections in burn or blast wounds suffered by soldiers.

2 Sep 2010

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2010.

16 Jul 2010

Aggressive infection control measures stop spread of Acinetobacter baumannii at Dallas hospital

Rapid identification and aggressive infection control measures allowed a Dallas hospital to stop the spread of Acinetobacter baumannii, a type of bacteria that has become increasingly prevalent in healthcare facilities and is resistant to most antibiotics. The findings were presented today at the 37th Annual Conference and International Meeting of the Association for Professionals in Infection Control and Epidemiology.

13 Jul 2010

Effective compound against antibiotic-resistant biofilms

Researchers at North Carolina State University have found a chemical compound that, when used in conjunction with conventional antibiotics, is effective in destroying biofilms produced by antibiotic-resistant strains of bacteria such as the Staphylococcus strain MRSA and Acinetobacter. The compound also re-sentsitizes those bacteria to antibiotics.

9 Apr 2010

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Kenta Biotech today announced an agreement with Rentschler Biotechnologie for the development of a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).

18 Jan 2010

U.S. army Phase I STTR contract for Intralytix

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR contract supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

9 Oct 2009

Phase IIa trial results of panobacumab released

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates.

14 Sep 2009

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.

9 Sep 2009

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii).

3 Sep 2009

Biologist demystifies Acinetobacter baumannii

Tao Weitao, a researcher in the College of Sciences' Department of Biology at the University of Texas at San Antonio is making great strides in a project that was funded one year ago by the San Antonio Area Foundation. The professor in the South Texas Center for Emerging Infectious Diseases is researching Acinetobacter baumannii, a soil-dwelling bacterium that threatens the health of military personnel in the Middle East and can also infect their family members once the soldiers have returned home following battle.

17 Aug 2009

Machine designed to reduce infections and cut back on expensive "disposables"

Johns Hopkins experts in applied physics, computer engineering, infectious diseases, emergency medicine, microbiology, pathology and surgery have unveiled a 7-foot-tall, $10,000 shower-cubicle-shaped device that automatically sanitizes in 30 minutes all sorts of hard-to-clean equipment in the highly trafficked hospital emergency department.

30 Jul 2009